ArticleCambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees2022
Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care.
Article in Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 31 citations in OpenAlex.
- Ketamine-induced analgesia and dissociation show distinct behavioral and neural correlates.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.Journal of psychopharmacology (Oxford, England) · 2026Article
- Ethical Issues and Recommendations in Psychedelic Research and Practice: A Scoping Review.Journal of bioethical inquiry · 2026Article
- Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.Current topics in behavioral neurosciences · 2026Review
- Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review.Psychological medicine · 2025Article
- Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.Psychopharmacology · 2025Review
- The Psychedelic Renaissance: A Catholic Perspective.The Linacre quarterly · 2025Article
- Virtual reality and psychedelics: new perspectives and new possibilities in the treatment of alcohol use disorder.Frontiers in psychiatry · 2025Review
- Personal psychedelic experience of psychedelic therapists during training: should it be required, optional, or prohibited?International review of psychiatry (Abingdon, England) · 2024Review
- Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.Psychedelic medicine (New Rochelle, N.Y.) · 2024Article
- Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon.Cancers · 2024Review
- Giving Consent to the Ineffable.Neuroethics · 2024Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence suggests that psychedelics bring about their therapeutic outcomes in part through the subjective or qualitative effects they engender and how the individual interprets the resulting experiences. However, psychedelics are contraindicated for individuals who have been diagnosed with certain mental illnesses, on the grounds that these subjective effects may be disturbing or otherwise counter-therapeutic. Substantial resources are therefore currently being devoted to creating psychedelic substances that produce many of the same biological changes as psychedelics, but without their characteristic subjective effects. In this article, we consider ethical issues arising from the prospect of such potential "nonsubjective" psychedelics. We are broadly supportive of efforts to produce such substances for both scientific and clinical reasons. However, we argue that such nonsubjective psychedelics should be reserved for those special cases in which the subjective effects of psychedelics are specifically contraindicated, whereas classic psychedelics that affect subjective experience should be considered the default and standard of care. After reviewing evidence regarding the subjective effects of psychedelics, we raise a number of ethical concerns around the prospect of withholding such typically positive, meaningful, and therapeutic experiences from most patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.